Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease

Arthritis Care and Research

Volumn 62, Issue 12, 2010, Pages 3730-3740

  Sato, Takeshi ^a   Fujii, Takao ^a   Yokoyama, Tomoko ^a   Fujita, Yoshimasa ^b   Imura, Yoshitaka ^c   Yukawa, Naoichiro ^a   Kawabata, Daisuke ^a   Nojima, Takaki ^a   Ohmura, Koichiro ^a   Usui, Takashi ^a   Mimori, Tsuneyo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CLOXAZOLAM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIAZEPAM; DOUBLE STRANDED DNA ANTIBODY; FLUNITRAZEPAM; IMMUNOGLOBULIN G; INTERLEUKIN 6; LA ANTIBODY; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SM ANTIBODY; TUBERCULOSTATIC AGENT; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN; ZOLMITRIPTAN; AMINO ACID; RNA;

ACUTE CONFUSION; ADULT; ANTIBODY BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASEPTIC MENINGITIS; BLOOD BRAIN BARRIER; CENTRAL NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; DEMYELINATING DISEASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPRECIPITATION; INTRACTABLE PAIN; LOW DRUG DOSE; MALE; MENTAL DISEASE; MIGRAINE; MILIARY TUBERCULOSIS; MIXED CONNECTIVE TISSUE DISEASE; MOTOR DYSFUNCTION; PLASMAPHERESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DOMAIN; PSYCHOSIS; RNA BINDING; SEIZURE; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIBODY PRODUCTION; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; SERUM;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-6; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR;

EID: 78650072950     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27700     Document Type: Article

References (45)

1. Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME,. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 2005; 4: 329-44.
2. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K,. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156-62.
3. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity: antibody impairs memory. Immunity 2004; 21: 179-88.
4. Sakic B, Maric I, Koeberle PD, Millward JM, Szechtman H, Maric D, et al. Increased TUNEL staining in brains of autoimmune Fas-deficient mice. J Neuroimmunol 2000; 104: 147-54.
5. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl- D -aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505-14.
6. Harrison MJ, Ravdin LD, Lockshin MD,. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2515-22.
7. Arinuma Y, Yanagida T, Hirohata S,. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1130-5.
8. Isshi K, Hirohata S,. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1819-27.
9. Yoshio T, Hirata D, Onda K, Nara H, Minota S,. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32: 34-9.
10. Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, Blank M, et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007; 56: 938-48.
11. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312-24.
12. Zandman-Goddard G, Chapman J, Shoenfeld Y,. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36: 297-315.
13. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009; 60: 2418-27.
14. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB,. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol 2009; 182: 34-8.
15. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB,. Potent induction of IFN-α and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009; 182: 1192-201.
16. Okada J, Hamana T, Kondo H,. Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases. Scand J Rheumatol 2003; 32: 247-52.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
18. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
19. Kasukawa R, Tojo T, Miyawaki S, Yoshida H, Tanimoto K, Nobunaga M, et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In:, Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Excerpta Medica; 1987. p. 41-7.
20. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
21. Kwiecinski J, Klak M, Trysberg E, Blennow K, Tarkowski A, Jin T,. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2094-101.
22. Abbott NJ, Mendonca LL, Dolman DE,. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003; 12: 908-15.
23. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233-41.
24. Query CC, Bentley RC, Keene JD,. A common RNA recognition motif identified within a defined U1RNA binding domain of the 70K U1 snRNP protein. Cell 1989; 57: 89-101.
25. Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Diamond B, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus: implications for diagnosis and pathogenesis. PLoS One 2008; 3: e3347.
26. Colasanti T, Delunardo F, Margutti P, Vacirca D, Piro E, Siracusano A, et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 2009; 212: 3-9.
27. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H, and the NPSLE Research Subcommittee. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis: a multicenter retrospective study. Clin Rheumatol 2009; 28: 1319-23.
28. Hirohata S, Hirose S, Miyamoto T,. Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus: their use as estimates of central nervous system disease activity. Arch Intern Med 1985; 145: 1843-6.
29. Winfield JB, Shaw LM, Silverman LM, Eisenberg HA, Wilson HA III, Koffler D,. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 1983; 74: 837-44.
30. Winfield JB, Brunner CM, Koffler D,. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 1978; 21: 289-94.
31. Fujita Y, Fujii T, Nakashima R, Tanaka M, Mimori T,. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol 2008; 18: 184-8.
32. Herbst F, Artlich A, Neuhauser G, Gortner L, Diehl M, Risse J,. MCTD in the differential diagnosis of cerebellar ataxia. Klin Pediatr 2001; 213: 332-3.
33. Mimori T,. Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. Intern Med 1999; 38: 23-32.
34. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1242-50.
35. Okamoto H, Katsumata Y, Nishimura K, Kamatani N,. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004; 50: 3731-2.
36. Iikuni N, Okamoto H, Yoshio T, Sato E, Kamitsuji S, Iwamoto T, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL-2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 253-6.
37. Sanarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmocytoid dendritic cells through TLR7. Blood 2006; 107: 3229-34.
38. Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida YB, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 953-7.
39. Yoshio T, Masuyama JI, Kano S,. Anti-ribosomal P0 protein antibodies to the ribosomal P proteins react the surface of human umbilical vein endothelial cells. J Rheumatol 1996; 23: 1311-2.
40. Greidinger EL, Foecking MF, Schafermeyer KM, Bailey CW, Primm SL, Lee DR, et al. T cell immunity in connective tissue disease patients targets the RNA binding domain of the U1-70kDa small nuclear ribonucleoprotein. J Immunol 2002; 169: 3429-37.
41. Guldner HH, Netter HJ, Szostecki C, Lakomek HJ, Will H,. Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera. J Immunol 1988; 141: 469-75.
42. Cram DS, Fisicaro N, Coppel RL, Whittingham S, Harrison LC,. Mapping of multiple B cell epitopes on the 70-kilodalton autoantigen of the U1 ribonucleoprotein complex. J Immunol 1990; 145: 630-5.
43. Mahler M, Bluthner M, Polland KM,. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003; 107: 65-79.
44. Monneaux F, Muller S,. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins. Scand J Immunol 2001; 54: 45-54.
45. James JA, Scofield RH, Harley JB,. Basic amino acids predominance in the sequential autoantigenic determinants of the small nuclear 70K ribonucleoprotein. Scand J Immunol 1994; 39: 557-66.